Skip to content

Kynurenine Pathway Combined with Neuroimaging to Investigate the Mechanisms of Suicidal Ideation in Major Depressive Disorders and to establish an early-identification model

Kynurenine Pathway Combined with Neuroimaging to Investigate the Mechanisms of Suicidal Ideation in Major Depressive Disorders and to establish an early-identification model

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500109936
Enrollment
Unknown
Registered
2025-09-28
Start date
2025-10-20
Completion date
Unknown
Last updated
2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorders

Interventions

MDD and Health Control Group:none

Sponsors

Tianjin Anding Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: MDD: (1) Meet the diagnostic criteria for "major depressive disorder" as outlined in the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5); (2) HAMD-17 score >= 14 points; (3) Age 18–65 years; (4) First episode; (5) No prior use of any psychiatric medications, or no psychiatric medication treatment within the past 14 days; (6) Planned use of a single type of antidepressant medication; (7) Right-handed; (8) Patient and family members have signed an informed consent form. Healthy control: (1) healthy people matched with the sex, age and education level of the case group; (2) Han nationality; (3) Sign the informed consent form.

Exclusion criteria

Exclusion criteria: MDD: (1) Currently or previously diagnosed with a mental disorder other than depressive disorder according to DSM-5 criteria; (2) History of severe organic diseases or conditions affecting major systems or organs; (3) Pregnant or breastfeeding women; (4) Received physical therapy within the past 3 months; (5) Participated in an interventional clinical trial within the past 3 months; (6) Presence of electronic or metallic implants in the body; (7) Transitioned to a manic phase during follow-up; (8) Participants deemed by the investigator to have poor compliance or unsuitability for the study. Healthy control: (1) having serious physical diseases and brain organic diseases; (2) having any mental disorder in DSM-5; (3) have a family history of mental illness or suicide; (4) Suicidal behavior in the past or suicidal thoughts at present; (5) Refusing to participate in this study.

Design outcomes

Primary

MeasureTime frame
Suicide Ideation;

Secondary

MeasureTime frame
Depression severity;Anxiety severity;Anhedonia;

Countries

China

Contacts

Public ContactTian Xue

Tianjin Anding Hospital

576491743@qq.com+86 136 0218 2093

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026